Repligen Corporation WALTHAM, Mass., – Repligen Corporation (Nasdaq:RGEN) announced today that it has acquired the business of Refine Technology (“Refine”), including Refine’s Alternating Tangential Flow (“ATF”) System, a market-leading device used to significantly increase product yield during the fermentation step of the biologic drug manufacturing process. The acquisition strengthens Repligen’s bioprocessing business by adding a profitable and highly complementary product line while expanding the Company’s direct sales presence worldwide. Repligen has entered into a definitive agreement effective June 2, 2014…